NCT01978743View on ClinicalTrials.gov

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

January 31, 2017

Conditions
HIVHIV-associated Neurocognitive DisorderNeurotoxicity
Interventions
DRUG

Raltegravir

Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks

Trial Locations (1)

02115

Brigham and Women's hospital, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01978743 - Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen | Biotech Hunter | Biotech Hunter